Answers are grounded in this paper and cite their sources.
Introduction Azathioprine has been used extensively for immunosuppression in autoimmune disease and organ transplantation for over 25 years. Despite extensive clinical experience much of the drug's pharmacodynamic and pharmacokinetic characteristics are unknown; its mode of action at the immune cell level remains unclear. The azathioprine structure was synthesized to protect the sulphydryl group of 6-mercaptopurine (6-MP) from in vivo methylation but, subsequent studies have shown that after an oral dose azathioprine is rapidly converted to 6-MP'2 which in turn undergoes extensive metabolism along three competing routes (Figure 1). In vivo methylation is a major catabolic pathway catalysed by the enzyme thiopurine methyltransferase (TPMT). Wide interindividual differences in TPMT activity exist which are controlled by a common genetic polymorphism3. Eighty nine per cent of the population have high and 11% intermediate enzyme activities whilst one in 300 subjects has very low or absent TPMT activity. A second catabolic route is oxidation catalysed by xanthine oxidase. Measurements offunctional xanthine oxidase activity have shown that there is little interindividual or interethnic variation of enzyme activity in the normal population4, whilst direct measurements of hepatic xanthine oxidase activities in biopsy tissue report a 3.9-fold variation5. Active nucleotide metabolites are produced by the third route which is catalysed by the enzyme hypoxanthine phosphoribosyl transferase. This pathway is responsible for the formation of several intracellular active metabolites. The major active metabolites in the human red blood cell (RBC) are the 6-thioguanine nucleotides (6-TGN). Active nucleotide metabolites of azathioprine, which include 6-TGN, are responsible for both cytotoxicity and the suppression of de novo purine synthesis. Both mechanisms contribute to the immunosuppressive properties of azathioprine but, in vitro evidence suggests that this may not be the sole mechanism of action6. We have reviewed the literature and identified cases of severe myelosuppression associated with azathioprine. In addition we report a further case of acute and profound bone marrow suppression which developed shortly after onset of treatment with azathioprine. This was associated with abnormally high concentrations of the azathioprine cytotoxic metabolites 6-TGNs and a very low inherited level of the enzyme TPMT. This is the second case we have seen ofearly and profound myelosuppression associated with azathioprine used in conventional doses for the treatment of oral lichen planus. The first case has previously been reported7 8.
No takes yet. Share an insight, caveat, or question.
Anstey et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: